mnia time, and since the large majority of organs can be allocated locally or regionally, it will also significantly reduce transportation costs. While dealing with a life-saving but scarce medical resource, a continuous and open-minded discussion is the only way to maintain a well-balanced and socially acceptable equipoise between equity, utility and efficiency.

References

1. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725–1730
2. De Meester J, Persijn GG, Wujciak T et al. Eurotransplant International Foundation. The new Eurotransplant kidney allocation system: report one year after implementation. Transplantation 1998; 66: 1154–1159
3. Glander P, Budde K, Schmidt D et al. The ‘blood group O problem’ in kidney transplantation—time to change? Nephrol Dial Transplant 2010; 25: 1998–2004
4. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002; 74: 1377–1381
5. de Klerk M, Wituveit MD, Haase-Kromwijk BJ et al. Hurdles, barriers, and successes of a national living donor kidney exchange program. Transplantation 2008; 86: 1749–1753
6. Doxiadis II, Smits JM, Persijn GG, Frei U, Claas FH. It takes six to boogie: allocating cadaver kidneys in Eurotransplant. Transplantation 2004; 77: 615–617
7. Doxiadis II, de Fijter JW, Mallat MJ et al. Simpler and equitable allocation of kidneys from postmortem donors primarily based on full HLA-DR compatibility. Transplantation 2007; 83: 1207–1213
8. Rudge C, Johnson RJ, Fuggle SV, Forsythe JL. Renal transplantation in the United Kingdom for patients from ethnic minorities. Transplantation 2007; 83: 1169–1173
9. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88: 447–452
10. de Fijter JW. An old virtue to improve senior programs. Transpl Int 2009; 22: 259–268
11. Rao PS, Merion RM, Ashby VB, Port FK, Wolfe RA, Kayler LK. Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. Transplantation 2007; 83: 1069–1074
12. Kasiske BL, Snyder J. Matching older kidneys with older patients does not improve allograft survival. J Am Soc Nephrol 2002; 13: 1067–1072
13. Frei U, Noelske J, Machold-Fabrizii V et al. Prospective age-matching in elderly kidney transplant recipients—a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant 2008; 8: 50–57
14. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539–1543

Received for publication: 26.2.10

Nephrol Dial Transplant (2010) 25: 1749–1753
doi: 10.1093/ndt/gfq145
Advance Access publication 26 March 2010

Proteomics and peritoneal dialysis: early days but clear potential*

Ian A. Brewis and Nicholas Topley

Department of Infection, Immunity and Biochemistry, School of Medicine, Cardiff University, Heath Park, Cardiff, CF14 4XN, UK

*Invited editorial comment on ‘Differential proteomic characterization between normal peritoneal fluid and diabetic peritoneal dialysate’ by Wang et al. (NDT-00368-2009) [1].

Keywords: biomarker; dialysis; peritoneal fluid; proteomics

Global analysis of proteins

The application of proteomics (the study of protein products expressed by the genome) has become one of the leading post-genomic technologies given the increased understanding of the central role of proteins and protein–protein interactions in all aspects of cellular function [2]. Systematic global identification and quantification of proteins can, not only inform improved biomedical understanding of a particular system in healthy or diseased individuals, but also be used for protein biomarker discovery. The most popular of the many proteomic strategies available are summarized in Figure 1 and, whilst two-dimensional electrophoresis (2DE) gel-based approach remains popular, liquid chromatography–tandem mass spectrometry (LC-MS/MS) and gel electrophoresis then liquid chromatography mass spectrometry (gELC-MS) approaches are now preferred as state-of-the-art.

Protein biomarker discovery has been a major driving force for the field and abundant scientific evidence from proteomics and other disciplines strongly suggests that most, if not all, diseases will result in changes in certain
Fig. 1. Strategies for the global identification and quantification of proteins. Proteins may be derived from biological fluids or solubilized from entire cells or their subcellular fractions. One option with biological fluids is to use proprietary immunodepletion methods (A) to remove up to 20 of the most abundant proteins in order to more readily analyse the lower abundance proteins. Following solubilization, proteins may be separated by 2DE (B). In this workflow, an individual separated protein is removed as a gel plug, trypsin digested and the resulting peptides are typically separated on the basis of relative hydrophobicity by nanoscale LC. The amino acid sequence of these peptides is then determined by MS/MS [19,20] and this data is used to search existing protein databases to achieve a match and, therefore, a protein identification (ID). One can process multiple gel plugs to identify many of the 2DE-separated proteins. The method of choice for 2DE protein quantification is DIGE (C) whereby samples are labelled with different fluorescence dyes prior to mixing together (multiplexing) and 2DE [16]. Such gel-based proteomics remains popular, but for global analysis, it is now more commonplace to trypsin digest the entire solubilized protein mixture to produce a peptide ‘soup’ of all the proteins in the sample (gel-free LC-MS/ MS proteomics) (D). Peptides are then separated by LC on the basis of relative hydrophobicity and often also charge as a multidimensional separation. Then, extensive MS/MS and database searches are performed to identify many (ideally all) of the proteins in the original sample. One of the advantages of this workflow is that it is possible to achieve simultaneous quantitative data by introducing an iTRAQ labelling step (E) (or other labelling step) following trypsin digestion without the need for additional LC-MS/MS [17,18]. A further method for global protein identification is to first separate proteins by one-dimensional electrophoresis (1DE) before subjecting individual protein bands to digestion and LC-MS/MS (the gelLC-MS workflow) (F). Whilst this is an excellent workflow for high numbers of protein IDs, it is not particularly amenable to protein quantification methodologies. Finally, there are many other options. For example, one may enrich for peptides or proteins of a particular type to study a particular group of proteins and this is most commonly performed for phosphorylation analysis. Peptide isoelectric focussing (IEF) as an additional step within the usual LC-MS/MS workflow is a valid option for increased numbers of IDs and protein LC can also be performed prior to trypsin digestion. Finally, SELDI-TOF MS ProteinChip technology may be potentially used for biomarker discovery, although the approach has certain limitations [21].
proteins in plasma [3]. This primary clinical specimen is usually chosen for analysis but other biological fluids will also likely contain protein profiles indicative of homeostasis or diseases in that locale or organ system. For example, urine has been the focus of a number of studies in relation to kidney and bladder diseases [4,5] and cerebrospinal fluid has also received a good deal of attention for neurological conditions [6]. There have been very few proteomic investigations of clinical effusion materials (pleural, pericardial and peritoneal) [7] with preliminary reports on peritoneal fluid limited to studying endometriosis [8] and ovarian cancer [7,9].

**Proteomics to study peritoneal dialysis**

One of the reasons why there have been so few studies on peritoneal effusions is that the material is not straightforward to obtain. Peritoneal dialysis (PD) is a highly effective and convenient mode of renal replacement therapy and offers the unique opportunity for access to and analysis of peritoneal dialysis effluents (PDE) from all types of patients. Whilst not the same as peritoneal effusions, this fluid is nonetheless a clinically relevant sample that can be analysed to provide critical information about PD specifically as well as the peritoneal environment more generally. Several groups have recently taken on this challenge and produced preliminary proteomics studies on PDE [1,10–14].

The paper in this edition by Wang et al. [1] is the first study to show proteomic differences between diabetic peritoneal PD and normal peritoneal fluid (five patients and two controls). Following 2DE analysis, a number of these proteins were confirmed by western blotting and included vitamin D-binding protein, haptoglobin and α-2 macroglobulin at raised levels and complement component C4A and immunoglobulin κ at lower levels. The authors propose that the loss of vitamin D-binding protein, haptoglobin and α-2 macroglobulin may be due to a change in the permeability of the peritoneal membrane to medium-sized proteins or leakage due to peritoneal inflammation. They also suggest that lower levels of C4A in the dialysate may shed light on the mechanisms responsible for the initiation of peritoneal membrane scleroses. Only limited studies on the role of immunoglobulin κ in the peritoneum have been reported and lower levels in the dialysate may provide a novel aspect for peritoneal change during PD therapy. Whilst preliminary in nature, the identification of protein differences between normal fluid and diabetic PDE provides useful information for more detailed follow-up studies.

Altered levels of C4A and immunoglobulin κ were also revealed in the first published proteomic analysis on PDE using a cohort of 20 chronic PD patients with varying transport rates [12]. Following 2DE, five proteins were identified with significantly different levels among the transport groups. In particular, increased levels of C4A and immunoglobulin κ in higher transport versus lower transport patients were confirmed in a further validation set of 24 patients by ELISA. This further emphasizes the value in further exploring these two proteins and demonstrates that proteomics can be used to compare differences between different patient sub-groups.

The only other significant PD proteomic study used a more sophisticated methodology (gelC-MS) with nine paediatric PD patients to identify a total of 189 PDE proteins with 88 shared by all patients [10]. Unlike the previous two studies, no comparisons were made between different sample types but analysis of the protein list revealed that the majority of proteins identified were derived from the extracellular matrix (84 compared with 11% plasma proteins) reflecting the clear retention of PD fluid within the extracellular space. Hence, proteomics can also potentially provide clinically relevant information about localization of and changes in proteins in the peritoneal membrane. There is clear relevance here to pathological alterations in the peritoneal membrane described in the biopsy registry study [15]. This proteome also revealed a number of new proteins such as gelsolin and intelectin that had not been previously reported in PDE. One of the exciting aspects of proteomics technology is that it allows for the discovery of previously unknown proteins in a particular sample which can then lead to the generation of new hypotheses. In this case, gelsolin has been proposed to be a marker for sepsis but in PD might play a protective role in mesothelial cell damage and against infection. Intelectin (also called omentin) is an adipocytokine with a possible role in defence against intestinal bacterial permeation and parasites and may be of relevance to host defence in the peritoneal cavity.

Finally, two other studies have used proteomic methods on PDE. In one study, 2DE and surface-enhanced laser desorption/ionization mass spectrometry (SELDI-TOF MS) were performed on PDE from 16 patients with peritonitis and β2-microglobulin was further proposed as a biomarker for PD peritonitis [11]. In the other study, 2DE and SELDI-TOF MS were again used and a total 21 proteins were identified from PDE but no significant conclusions were drawn [14].

**Time now for more extended studies**

The proteomic studies to date on PDE have only been very preliminary and further prospective studies with greater numbers of patients might enable sub-group analyses to yield additional information about changes in peritoneal dialysate proteins that are associated with specific phenotypes, for example, association with membrane function, residual renal function, nutritional status, the risk of peritoneal infection and fibrosis or the onset of encapsulating peritoneal sclerosis [12]. From this, conclusions might be directly drawn or this information could be used to inform further more focused investigation.

The number of proteins identified in PDE studies to date is small with only one managing over 30 proteins [10] and many much less than this. With so many more proteins remaining to be discovered or confirmed, the challenge now is to adopt the range of workflow choices (see Figure 1) in order to produce more comprehensive protein lists. Each workflow will reveal certain unique proteins not found with the other methodologies; so, for maximum proteomic coverage, a combination of several approaches is recommended. Whilst expensive and technically challenging, such efforts will enable novel proteins to be identified to enable new hy-
Changes in proteins. PDE and necessary for the quantification of more subtle
changes in abundance between the most and the least abundant proteins [17,18], as gold standards for relative protein quantification (see Figure 1). These are more statistically robust than 2DE gel-to-gel comparison approaches used to date on PDE and necessary for the quantification of more subtle changes in proteins.

**The Achilles’ heel of proteomics**

As a note of caution, the analysis of biological fluids, including PDE, is not straightforward. The huge potential for biomedical and biomarker discovery is limited by the considerable challenge of identifying the lowest abundant proteins which may often be the most biologically relevant or the likely source of biomarkers. In biological fluids, there are typically well over 10 orders of magnitude differences in abundance between the most and the least abundant proteins [3]. As the analytical technologies generally have 2–4 orders of magnitude dynamic range for protein detection, there is clearly a shortfall and not all proteins can currently be identified using these methods alone.

All is not lost, however, as these technologies still do identify proteins that have not been previously identified in given systems and hence produce highly valuable information. Immunodepletion methods can be used to remove the 20 or so most abundant proteins (~97% of the total protein content for plasma), but this is not sufficient to solve the problem and additionally interesting proteins might be lost that bind to these common proteins. There are also certain other sample fractionation approaches that may be employed to improve specificity, but paradigm changes in proteomics technology will be necessary for all proteins to be identified.

**Looking to the future**

Whilst preliminary in nature, the PDE proteomics studies performed to date do reveal how proteomics can be used to potentially further understand PD. Whilst PD replaces the function of the kidney, pathological damage of the peritoneum is a frequent occurrence and cannot be easily identified without invasive techniques. Proteins identified from PDE may provide insights and facilitate the non-invasive discovery of potential biomarkers for measuring peritoneal damage and changes in transport. Additionally, the effect of different dialysis fluids or the impact of infection and/or prolonged PD duration on protein profiles might also be investigated to provide improved understanding of the pathological processes that remain the barrier to wider acceptance and utilization of the therapy.

Further detailed proteomics studies are now warranted in this field and will undoubtedly provide improved biomedical understanding and may also lead to novel biomarker discovery for the diagnosis, prognosis and therapeutic monitoring of pathological events related to PD. Clinical proteomics is still in its infancy but does have the potential for ‘bedside’ applications. In time, there is every reason to believe that this technology platform will also make key contributions to both the understanding and utilization of PD.

**Conflict of interest statement.** None declared.

**References**

1. Wang HY, Tian YF, Chien CC *et al.* Differential proteomic characterisation between normal peritoneal fluid and diabetic peritoneal dialysate. *Nephrol Dial Transplant* 2010; 25: 1955–1963
2. Cox J, Mann M. Is proteomics the new genomics? *Cell* 2007; 130: 395–398
3. Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. *Mol Cell Proteomics* 2002; 1: 845–867
4. Muller GA, Muller CA, Dihazi H. Clinical proteomics—on the long way from bench to bedside? *Nephrol Dial Transplant* 2007; 22: 1297–1300
5. Thongboonkerd V. Current status of renal and urinary proteomics: ready for routine clinical application? *Nephrol Dial Transplant* 2010; 25: 11–16
6. Lewczuk P, Wiltfang J. Neurochemical dementia diagnostics: state of the art and research perspectives. *Proteomics* 2008; 8: 1292–1301
7. Tyan Y, Liao P. Proteomics analysis of serous fluid and effusions: pleural, pericardial and peritoneal. *Proteomics Clin Appl* 2007; 1: 834–844
8. Ferrero S, Gillott DJ, Remorgida V *et al.* Proteomic analysis of peritoneal fluid in women with endometriosis. *J Proteome Res* 2007; 6: 3402–3411
9. Davidson B, Espina V, Steinberg SM *et al.* Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling. *Clin Cancer Res* 2006; 12: 791–799
10. Raaijmakers R, Pluk W, Schroder CH *et al.* Proteomic profiling and identification in peritoneal fluid of children treated by peritoneal dialysis. *Nephrol Dial Transplant* 2008; 23: 2402–2405
11. Lin WT, Tsai CC, Chen CY *et al.* Proteomic analysis of peritoneal dialysate fluid in patients with dialysis-related peritonitis. *Ren Fail* 2008; 30: 772–777
12. Sririppayawan S, Chiangjong W, Semagoon T *et al.* Proteomic analysis of peritoneal dialysate fluid in patients with different types of peritoneal membranes. *J Proteome Res* 2007; 6: 4356–4362
13. Thongboonkerd V. Proteomics in extracorporeal blood purification and peritoneal dialysis. *J Proteomics* 2010; 73: 521–526
14. Dihazi H, Muller CA, Mattes H *et al.* Proteomic analysis to improve adequacy of hemo- and peritoneal dialysis: removal of small and high molecular weight proteins with high- and low-flux filters or a peritoneal membrane. *Proteomics Clin Appl* 2008; 2: 1167–1182
15. Williams JD, Craig KJ, Topley N *et al.* Morphologic changes in the peritoneal membrane of patients with renal disease. *J Am Soc Nephrol* 2002; 13: 470–479
16. Lilley KS, Friedman DB. All about DIGE: quantification technology for differential-display 2D-gel proteomics. *Expert Rev Proteomics* 2004; 1: 401–409
17. Zieske LR. A perspective on the use of iTRAQ reagent technology for protein complex and profiling studies. *J Exp Bot* 2006; 57: 1501–1508
18. Unwin RD, Evans CA, Whetton AD. Relative quantification in proteomics: new approaches for biochemistry. *Trends Biochem Sci* 2006; 31: 473–484
Catheter-related blood stream infections (CRBSI): a European view

Raymond Vanholder¹, Bernard Canaud², Richard Fluck³, Michel Jadoul⁴, Laura Labriola⁴, Anna Martí-Monros⁵, Jan Tordoir⁶ and Wim Van Biesen¹

¹Nephrology Section, Department of Internal Medicine, University Hospital, Gent, Belgium, ²Nephrology, Dialysis and Intensive Care Unit, Lapeyronie University Hospital, Montpellier, France, ³Department of Renal Medicine, Royal Derby Hospital, Derby, UK, ⁴Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium, ⁵Nephrology Department, Consorcio Hospital General Universitario, Valencia, Spain and ⁶Vascular Surgery, Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands

Correspondence and offprint requests to: Raymond Vanholder; E-mail: raymond.vanholder@ugent.be

In the July 2009 issue of the journal Clinical Infectious Diseases, the Infectious Diseases Society of America (IDSA) published an update of their ‘Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection’ [1]. The largest part of the IDSA text relates to non-dialysis catheters, and it is not always clear to what extent these general recommendations can be extrapolated to the haemodialysis condition. A specific but only brief section (~2 pages) of the IDSA guidelines is devoted to haemodialysis catheters.

In a position statement published in the June issue of NDT Plus [2] by the European Renal Best Practice (ERBP), these IDSA guidelines are amended with focus on haemodialysis conditions. ERBP is the new guidance body of the European Renal Association–European Dialysis and Transplantation Association (ERA–EDTA) replacing European Best Practice Guidelines (EBPG) since 2008. In contrast to the IDSA Guidelines, the ERBP position statement contains not only a section on treatment but also one on prevention and is entirely devoted to haemodialysis catheters. The publication was written according to the new philosophy of ERBP [3,4] and conforms to previously published documents [5–7].

The current editorial review offers a summary of this monograph [2], highlighting the most relevant statements. The reader is referred to the full text for the proper recommendations, a more extended rationale and several dialectic reflections on the original IDSA guidelines. At the end, the text in NDT Plus contains also a list of research suggestions.

General: tunnelled vs non-tunnelled catheters

Central vein catheters as an access for chronic haemodialysis are discouraged, in accordance with the previous EBPG guidance [8], although they are lifesaving in a substantial proportion of the dialysed population, who have run out of native access possibilities. If the use of a central vein catheter seems unavoidable, preference should be given to cuffed, tunnelled catheters unless contraindications are present, since the barrier they impose against inoculation is more efficient than with non-tunnelled catheters. It is considered mandatory to remove non-tunnelled temporary catheters as soon as possible, even in the absence of complications, and to have them replaced preferentially by an arteriovenous fistula (AVF), an arteriovenous graft (AVG), or a tunnelled central vein catheter, in that order of preference.

Prevention of infection

Catheter insertion and position

Catheters should be inserted under strict aseptic circumstances and according to the conditions formulated by EBPG [8]. Due to the complication profile [9], the use of the femoral and subclavian vein positions is discouraged. The right internal jugular vein is the preferred location for insertion, followed by the left internal jugular vein.